Sign up to save your podcasts
Or
Share Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
CME credits: 0.25
Valid until: 16-02-2027
Claim your CME credit at https://reachmd.com/programs/cme/targeting-ckd-ap-at-the-source-key-mechanisms-and-treatments/37606/
Drs. Steven Fishbane and Maurizio Gallieni discuss chronic kidney disease-associated pruritus (CKD-aP), a prevalent and under-recognized complication of CKD. They review the epidemiology, pathophysiology, and treatment strategies supported by pivotal phase 3 trials and new European S2k guidelines, including the use of difelikefalin, a kappa-opioid receptor agonist. Additional insights from biomarker analyses in the KALM studies underscore the link between inflammation and pruritus severity, suggesting a dual mechanism of action for difelikefalin. The program emphasizes the importance of actively screening for CKD-aP and using validated tools to assess symptom burden in clinical practice.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 16-02-2027
Claim your CME credit at https://reachmd.com/programs/cme/targeting-ckd-ap-at-the-source-key-mechanisms-and-treatments/37606/
Drs. Steven Fishbane and Maurizio Gallieni discuss chronic kidney disease-associated pruritus (CKD-aP), a prevalent and under-recognized complication of CKD. They review the epidemiology, pathophysiology, and treatment strategies supported by pivotal phase 3 trials and new European S2k guidelines, including the use of difelikefalin, a kappa-opioid receptor agonist. Additional insights from biomarker analyses in the KALM studies underscore the link between inflammation and pruritus severity, suggesting a dual mechanism of action for difelikefalin. The program emphasizes the importance of actively screening for CKD-aP and using validated tools to assess symptom burden in clinical practice.
=